Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2022)

Inhibikase Therapeutics (IKT) has 3 years of Interest Coverage Ratio data on record, last reported at 928119.2 in Q1 2022.

  • On a quarterly basis, Interest Coverage Ratio fell 416962.55% to 928119.2 in Q1 2022 year-over-year; TTM through Dec 2022 was 3625721.6, a 489095.22% decrease, with the full-year FY2021 number at 741.16, down 673.17% from a year prior.
  • Interest Coverage Ratio reached 928119.2 in Q1 2022 per IKT's latest filing, down from 31907.98 in the prior quarter.
  • Over the last five years, Interest Coverage Ratio for IKT hit a ceiling of 52.08 in Q2 2020 and a floor of 928119.2 in Q1 2022.
  • A 3-year average of 109939.28 and a median of 222.54 in 2021 define the central range for Interest Coverage Ratio.
  • Peak YoY movement for Interest Coverage Ratio: plummeted 205.98% in 2021, then crashed 416962.55% in 2022.
  • Tracing IKT's Interest Coverage Ratio over 3 years: stood at 168.21 in 2020, then tumbled by 18869.2% to 31907.98 in 2021, then crashed by 2808.74% to 928119.2 in 2022.
  • Business Quant data shows Interest Coverage Ratio for IKT at 928119.2 in Q1 2022, 31907.98 in Q4 2021, and 28477.96 in Q3 2021.